Treatment‐related mortality at 1 year (mITT) · bullous pemphigoid
Doxycycline probably leads to lower treatment‐related mortality at 1 year (mITT) compared with prednisolone (moderate certainty).
1 finding from 1 review
Quality of life (DLQI) adjusted for baseline DLQI, disease severity, age, Karnovsky score, baseline versus week 52. A lower score is more favourable. · bullous pemphigoid
1 finding from 1 review
Number of participants with grade 3‐4 (severe or life‐threatening) treatment‐related adverse events at 1 year (raw data) · bullous pemphigoid
Doxycycline probably leads to lower number of participants with grade 3‐4 (severe or life‐threatening)… compared with prednisolone (moderate certainty).
1 finding from 1 review
Disease control · bullous pemphigoid
Doxycycline leads to lower disease control at 6 weeks (unadjusted raw data) compared with prednisolone (high certainty).
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Doxycycline 40 mg + azelaic acid gel showed no clear difference in physician‐assessed improvement in rosacea severity Investigator's… compared with doxycycline 40 mg + metronidazole gel (high certainty).
1 finding from 1 review
Clinician's Erythema Assessment ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
Doxycycline 40 mg + azelaic acid gel showed no clear difference in participant‐assessed improvement in rosacea severity Excellent… compared with doxycycline 40 mg + metronidazole gel (high certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Doxycycline 40 mg + azelaic acid gel showed no clear difference in proportion of participants with adverse event compared with doxycycline 40 mg + metronidazole gel (high certainty).
1 finding from 1 review